Yong-Qi Li1, Kai-Shan Tao, Ning Ren, Yi-Hu Wang. 1. Comprehensive Diagnostic and Therapeutic Center, Xijing Hospital, the Fourth Military Medical University, Xi'an 710033, Shaanxi Province, China. yongqil33@yahoo.com.cn
Abstract
AIM: To examine the effect of prostaglandin E2 (PGE2) on the expression of vascular endothelial growth factor (VEGF) mRNA in the human hepatocellular carcinoma (HCC) HepG2 cells and the possible involvement of c-fos protein in this process. METHODS: Human HCC HepG2 cells were divided into three groups treated respectively with PGE2, a combination of PGE2 and c-fos antisense oligodeoxynucleotide (ASO), and PGE2 plus c-fos sense oligodeoxynucleotide (SO). The expression of VEGF mRNA in HepG2 cells after different treatments was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The relative expression level of VEGF mRNA in HepG2 cells in each group was measured. RESULTS: Administration of PGE2 resulted in an increased expression of c-fos and VEGF mRNA in HepG2 cells. The relative expression level of c-fos mRNA reached the peak at 3 h (68.4+/-4.7%) after PGE2 treatment, which was significantly higher than that at 0 h (20.6+/-1.7%, P<0.01). Whereas, the highest expression level of VEGF mRNA was observed at 6 h (100.5+/-6.1%) after PGE2 treatment, which was significantly higher than that at 0 h (33.2+/-2.4%, P<0.01). C-fos ASO significantly reduced PGE2-induced VEGF mRNA expression in HepG2 cells. CONCLUSION: PGE2 increases the expression and secretion of VEGF in HCC cells by activating the transcription factor c-fos, promotes the angiogenesis of HCC and plays an important role in the pathogenesis of liver cancer.
AIM: To examine the effect of prostaglandin E2 (PGE2) on the expression of vascular endothelial growth factor (VEGF) mRNA in the humanhepatocellular carcinoma (HCC) HepG2 cells and the possible involvement of c-fos protein in this process. METHODS:Human HCC HepG2 cells were divided into three groups treated respectively with PGE2, a combination of PGE2 and c-fos antisense oligodeoxynucleotide (ASO), and PGE2 plus c-fos sense oligodeoxynucleotide (SO). The expression of VEGF mRNA in HepG2 cells after different treatments was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The relative expression level of VEGF mRNA in HepG2 cells in each group was measured. RESULTS: Administration of PGE2 resulted in an increased expression of c-fos and VEGF mRNA in HepG2 cells. The relative expression level of c-fos mRNA reached the peak at 3 h (68.4+/-4.7%) after PGE2 treatment, which was significantly higher than that at 0 h (20.6+/-1.7%, P<0.01). Whereas, the highest expression level of VEGF mRNA was observed at 6 h (100.5+/-6.1%) after PGE2 treatment, which was significantly higher than that at 0 h (33.2+/-2.4%, P<0.01). C-fosASO significantly reduced PGE2-induced VEGF mRNA expression in HepG2 cells. CONCLUSION:PGE2 increases the expression and secretion of VEGF in HCC cells by activating the transcription factor c-fos, promotes the angiogenesis of HCC and plays an important role in the pathogenesis of liver cancer.
Authors: M Bhattacharya; K Peri; A Ribeiro-da-Silva; G Almazan; H Shichi; X Hou; D R Varma; S Chemtob Journal: J Biol Chem Date: 1999-05-28 Impact factor: 5.157
Authors: E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham Journal: J Biol Chem Date: 1991-06-25 Impact factor: 5.157
Authors: Hiromichi Ito; Mark Duxbury; Eric Benoit; Thomas E Clancy; Michael J Zinner; Stanley W Ashley; Edward E Whang Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: M Casibang; S Purdom; S Jakowlew; L Neckers; F Zia; P Ben-Av; T Hla; L You; D M Jablons; T W Moody Journal: Lung Cancer Date: 2001 Feb-Mar Impact factor: 5.705
Authors: David Bishop-Bailey; Sara Calatayud; Timothy D Warner; Timothy Hla; Jane A Mitchell Journal: J Environ Pathol Toxicol Oncol Date: 2002 Impact factor: 3.567
Authors: L Oliveira-Ferrer; K Rößler; V Haustein; C Schröder; D Wicklein; D Maltseva; N Khaustova; T Samatov; A Tonevitsky; S Mahner; F Jänicke; U Schumacher; K Milde-Langosch Journal: Br J Cancer Date: 2013-12-05 Impact factor: 7.640